Featured Posts

Novartis receives Health Canada approval of its CAR-T cell therapy, Kymriah™

Novartis is pleased to announce that following a Priority Review, Health Canada has approved Kymriah™ (tisagenlecleucel/ CTL019) the first chimeric antigen receptor T cell (CAR-T) therapy to receive regulatory approval in Canada.

Posts Are Coming Soon
Stay tuned...
Recent Posts
Archive
Search By Tags
Follow Us
  • Facebook Basic Square
  • Twitter Basic Square

524 Bayfield Street North
P.O. Box 20005
Barrie, ON L4M 5E9
Canada

info@opacc.org

1-888-290-5496

  • Wix Facebook page
  • Wix Twitter page
  • Instagram Social Icon
  • LinkedIn Social Icon
  • YouTube Social  Icon